Business Wire

OAG

3.1.2020 10:02:03 CET | Business Wire | Press release

Share
Aeroflot Leads Europe’s Mega Airlines in OTP, According to OAG’s Punctuality League 2020

OAG , the world’s leading provider of travel data and insight, today released the results of the OAG Punctuality League 2020 , a comprehensive ranking of the world’s largest airlines and airports for on-time performance (OTP).

Aeroflot finished as the most punctual Mega Airline in Europe and second-most punctual mega in the world (OTP 86.30%). Five additional European carriers earned spots among the world’s Top 20 Mega Airlines, including Air France (7th ; OTP 79.92%), British Airways (14th ; OTP 76.18%), Lufthansa (15th ; OTP 73.96%) and easyJet (17th ; OTP 73.08%).

Jet2 (OTP 82.69%), the UK’s third-largest airline, ranked fifth among the Top 20 Low-Cost Carriers (LCCs) and finished 19th globally. Several other European carriers, including Iberia (11th ; OTP 84.06%), Siberia Airlines (12th ; OTP 83.88%) and Air Baltic (13th ; OTP 83.63%) also placed among the world’s most punctual airlines.

British Airways’ hub London Heathrow (LHR; OTP 75.27%) ranked 13th among Mega Airports—a notable accomplishment for the world’s most internationally connected airport .

“The global market is reaching near peak OTP,” said John Grant, senior analyst with OAG. “The rise in performance is led by Mega Airlines like Aeroflot, Delta and Air France, which are simultaneously expanding the number of operated flights and maintaining high OTP. We’re seeing success trickle down to the hubs they service, which benefits the entire travel ecosystem.”

Delta (OTP 83.56%) ranked as the No. 1 Mega Airline in the continental U.S. for a third-straight year. Atlanta Hartsfield-Jackson (4th , ATL; OTP 83.74%) led the list of Delta hubs placing among the world’s most on-time Mega Airports. The top three Mega Airports in the world were Moscow Sheremetyevo (SVO; OTP 86.87%), Tokyo Haneda (HND; OTP 86.60%), and Singapore Changi (SIN; OTP 84.03%). Los Angeles International (LAX; OTP 79.62%) and New York’s John F. Kennedy (JFK; OTP 77.87%) ranked 7th and 8th , respectively.

Download the full report for more insights from OAG’s Punctuality League 2020 .

About OAG

OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. OAG has global operations in the UK, USA, Singapore, Japan, Lithuania and China.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye